Seebri Breezhaler Dosage/Direction for Use

General target population: The recommended dosage of SEEBRI BREEZHALER is the once-daily inhalation of the content of one 50 microgram capsule using the SEEBRI BREEZHALER inhaler.
Special Populations: Renal impairment: SEEBRI BREEZHALER can be used at the recommended dose in patients with mild tomoderate renal impairment. In patients with severe renal impairment or end-stage renal diseaserequiring dialysis SEEBRI BREEZHALER should be used only if the expected benefit outweighs the potential risk. See Precautions and Pharmacology under Actions.
Hepatic impairment: No specific studies have been conducted in patients with hepatic impairment. SEEBRI BREEZHALER is predominantly cleared by renal excretion and therefore no major increase in exposure is expected in patients with hepatic impairment.
Geriatric patients: SEEBRI BREEZHALER can be used at the recommended dose in elderly patients 75 years of age and older.
Pediatrics patients: SEEBRI BREEZHALER should not be used in patients under 18 years of age, COPD is an indication of adults only.
Method of administration: SEEBRI BREEZHALER capsules must be administered only by the oral inhalation route and only using the SEEBRI BREEZHALER inhaler. SEEBRI BREEZHALER capsules must not be swallowed (see Overdosage).
SEEBRI BREEZHALER is recommended to be administered once-daily at the same time of the day each day. If a dose is missed, the next dose should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day.
SEEBRI BREEZHALER capsules must always be stored in the blister to protect from moisture, and only removed immediately before use.
When prescribing SEEBRI BREEZHALER patients should be instructed on correct use of the inhaler. Patients who do not experience improvement in breathing should be asked if they are swallowing the medicine rather than inhaling it.